OncoMatch/Clinical Trials/NCT06911710
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Is NCT06911710 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） for lymphoma, b-cell, aggressive non-hodgkin (b-nhl).
Treatment: CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） — This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Multiple Myeloma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 overexpression
Diagnosis of CD19+ ... confirmed by pathology and histology
Required: CD20 overexpression
Diagnosis of ... CD20+ ... confirmed by pathology and histology
Required: CD22 overexpression
Diagnosis of ... CD22+ ... confirmed by pathology and histology
Required: TNFSF13B overexpression
Diagnosis of ... BAFF+ ... confirmed by pathology and histology
Required: CD7 overexpression
Diagnosis of CD7+ refractory/relapsed T-lymphocyte lymphoma confirmed by pathology and histology
Required: BCMA overexpression
Positive expression of BCMA ... in myeloma cells by flow or immunohistochemistry
Required: GPRC5D overexpression
Positive expression of ... GPRC5D in myeloma cells by flow or immunohistochemistry
Required: CD47 overexpression
Positive tumor cell antigen test results (CD7 and/or CD19 and/or CD47) confirmed by immunohistochemistry or flow cytometry
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
subjects must have received adequate prior therapy, including at least: Anti-CD20 monoclonal antibody
Must have received: anthracycline-containing combination chemotherapy
subjects must have received adequate prior therapy, including at least: ... Anthracycline-containing combination chemotherapy
Must have received: proteasome inhibitor
Patients with relapsed/refractory multiple myeloma who have received at least 1 prior therapy (including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs)) or are resistant to proteasome inhibitors and/or immunomodulatory agents
Must have received: immunomodulatory drug
Patients with relapsed/refractory multiple myeloma who have received at least 1 prior therapy (including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs)) or are resistant to proteasome inhibitors and/or immunomodulatory agents
Must have received: stem cell transplant
disease relapse after having undergone stem cell transplantation to achieve complete remission
Lab requirements
Blood counts
hgb ≥ 60g/l (transfusion is allowed)
Kidney function
creatinine ≤1.5×uln
Liver function
total bilirubin ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction ≥50%; blood oxygen saturation >90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify